Detalles de la búsqueda
1.
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region.
Eur J Haematol
; 111(5): 748-756, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37565648
2.
Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?
Scand J Immunol
; 95(4): e13153, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35244285
3.
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.
Br J Haematol
; 188(5): 685-691, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31612478
4.
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Br J Haematol
; 183(2): 212-224, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30125946
5.
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Eur J Haematol
; 101(1): 68-77, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29569742
6.
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Cancer Immunol Immunother
; 66(1): 91-102, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815572
7.
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
Haematologica
; 102(3): 562-572, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27927767
8.
Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-ß.
Eur J Immunol
; 45(6): 1783-93, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25773885
9.
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Br J Haematol
; 182(4): 590-594, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28677818
10.
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile.
Cancer Immunol Immunother
; 62(1): 51-63, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22736254
11.
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.
J Hematol
; 12(4): 170-175, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37692865
12.
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.
Cancer Immunol Immunother
; 61(6): 865-79, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22086161
13.
Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.
J Clin Oncol
; 40(13): 1487-1496, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35077204
14.
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment.
Hemasphere
; 6(11): e794, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36325271
15.
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Leukemia
; 36(2): 476-481, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34564699
16.
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Front Immunol
; 12: 686768, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34276674
17.
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.
EJHaem
; 2(3): 525-529, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35844699
18.
Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years.
EJHaem
; 2(3): 400-412, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35844675
19.
A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1+ CLL cells.
EJHaem
; 2(3): 498-502, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35844694
20.
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.
Hemasphere
; 5(5): e564, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33912812